HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued Valuation [Seeking Alpha]
HilleVax, Inc. (HLVX)
Company Research
Source: Seeking Alpha
Several other studies have already been initiated using HIL-214 for the prevention of Norovirus-related gastroenteritis such as NOR-109, NOR-206, and NOR-215. The global viral gastroenteritis market size is expected to reach $9.5 billion by 2032; 60% of viral gastroenteritis cases occur as a result of Norovirus. HIL-216 is another Virus Like Particle Vaccine to target Norovirus and licensing for it was obtained to develop it outside of China; This vaccine is capable of targeting more genotypes of Norovirus compared to HIL-214. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » HilleVax, Inc. NASDAQ: HLVX ) is gearing up to report a critical catalyst in the coming months, which is going to provide significant proof of whether or not its Virus Like Particle [VLP] HIL-214 can prevent moderate-to-severe Norovirus-related acute gastroenteritis. In particular, it expects to report results from a phase 2/3 study using this
Show less
Read more
Impact Snapshot
Event Time:
HLVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HLVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HLVX alerts
High impacting HilleVax, Inc. news events
Weekly update
A roundup of the hottest topics
HLVX
News
- Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board [Yahoo! Finance]Yahoo! Finance
- HilleVax, Inc. (NASDAQ: HLVX) had its price target raised by analysts at JPMorgan Chase & Co. from $21.00 to $24.00. They now have an "overweight" rating on the stock.MarketBeat
- HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewswire
HLVX
Earnings
- 5/9/24 - Miss
HLVX
Analyst Actions
- 5/15/24 - JP Morgan
HLVX
Sec Filings
- 6/10/24 - Form 8-K
- 5/31/24 - Form 4/A
- 5/31/24 - Form SC
- HLVX's page on the SEC website